25. A polynucleotide comprising a nucleic acid sequence encoding a modified Rv3616c protein according to any one of claims 1 to 24.

26. The polynucleotide according to claim ~~26~~25, consisting of a nucleic acid sequence encoding a modified Rv3616c protein according to any one of claims 1 to 24.

27. The polynucleotide according to either claim 25 or 26 ~~or 27~~, comprising a sequence encoding a polypeptide according to any one of SEQ ID Nos: 163 to 169.

28. The polynucleotide according to either claim 25 or 26 ~~or 27~~, comprising a sequence encoding a polypeptide according to either of SEQ ID Nos: 179 or 180.

29. A fusion protein comprising a modified Rv3616c protein according to any one of claims 1 to 23 and an additional heterologous polypeptide.

30. A polynucleotide encoding a fusion protein according to claim 29.

31. A host cell which recombinantly expresses a modified Rv3616c protein according to any one of claims 1 to ~~23~~ 24 or a fusion protein according to claim 29.

32. Use of a modified Rv3616c protein according to any one of claims 1 to 24 in the manufacture of a medicament for the treatment, prevention or amelioration of TB.

33. Use of a modified Rv3616c protein, or a polynucleotide comprising a nucleic acid sequence encoding it, in the manufacture of a medicament for the treatment of latent TB, wherein said modified Rv3616c protein is selected from:

(a) a modified Rv3616c protein comprising a first polypeptide and a second polypeptide, the first polypeptide being located towards the N-terminus relative to the second polypeptide, and wherein:

(i) the first polypeptide is a contiguous sequence of at least 100 amino acids within residues 1-134 of SEQ ID No: 1; and

(ii) the second polypeptide is a contiguous sequence of at least 175 amino acids within residues 155-392 of SEQ ID No: 1;

wherein the first and second polypeptides are either directly linked or indirectly linked via a third polypeptide, wherein said third polypeptide corresponds to residues 135-154 in SEQ ID No:1 in which at least 1 amino acid has been deleted; or

(b) a modified Rv3616c protein comprising a first polypeptide and a second polypeptide, the first polypeptide being located towards the N-terminus relative to the second polypeptide, and wherein:

(i) the first polypeptide is a contiguous sequence of at least 100 amino acids within residues 1-134 of SEQ ID No: 1; and

(ii) the second polypeptide is a contiguous sequence of at least 175 amino acids within residues 155-392 of SEQ ID No: 1;

wherein the first and second polypeptides are either directly linked or indirectly linked via a third polypeptide, wherein said third polypeptide corresponds to residues 135-154 in SEQ ID No:1 in which at least a contiguous portion of at least 3 amino acids has been deleted; or

(c) a modified Rv3616c protein comprising a Rv3616c sequence in which at least one amino acid has been deleted from the region corresponding to residues 134-183 in SEQ ID No:1; or